TABLE 4:

Summary of antimicrobial susceptibility data from evaluable cases upon entry (day 0 (D0)) and withdrawal (WD), by treatment (clinical study)

Otic Solution—treated cases, successful outcomes (D0)Otic Solution—treated cases, failed outcomes (D0)Otic Solution—treated cases, failed outcomes (WD)
MIC range (µg/ml)(MIC50)*MIC range (µg/ml)(MIC50)*MIC range (µg/ml)(MIC50)*
Escherichia coli8–32 (n=6)84–16 (n=4)168–16 (n=3)16
Proteus mirabilis4–8 (n=2)NA4 (n=1)NA8 (n=1)NA
Pseudomonas aeruginosa>64 (n=5)NA64 to >64 (n=7)>64>64 (n=5)NA
Staphylococcus pseudintermedius2–8 (n=58)42–4 (n=16)44 (n=9)NA
Beta-haemolytic Streptococci species2 (n=6)NA2 (n=4)NA2 (n=4)NA
Malassezia pachydermatis0.008–0.25 (n=85)0.030.015–0.06 (n=23)0.030.008–0.06 (n=5)0.03